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Abstract 
Background: Hyperbilirubinaemia (bilirubin >51.3 μmol/L) alone is not indicative of severe malaria, and the immune 
response underlying hyperbilirubinaemia remains largely unexplored. Liver damage associated with hyperbilirubinae‑
mia may alter the expression of hepcidin, which regulates systemic iron by degrading ferroportin. For this study, the 
association between hepcidin and the levels of cytokines and chemokines in the serum of individuals with mild and 
severe vivax malaria and subjects with malaria with isolated hyperbilirubinaemia was evaluated.
Methods: Cytokines/chemokines and hepcidin were measured in individuals with mild (n = 72) and severe (n = 17) 
vivax malaria, as well as in the serum of subjects with vivax malaria with isolated hyperbilirubinaemia (n = 14) from the 
Brazilian Amazon between 2009 and 2013 by multiplex assay and ELISA, respectively. The polymorphism 744 G > T in the 
ferroportin gene was identified by restriction fragment‑length polymorphism analysis and the restriction enzyme PvuII.
Results: The polymorphism at position 744 G > T in the ferroportin gene was typed and no differences in the 
distributions of genotypes or alleles were observed between the study groups. Subjects with severe malaria had 
higher levels of interleukin (IL)‑2 and IL‑13 than subjects with hyperbilirubinaemia. No differences in the expression of 
immune markers were observed between subjects with mild malaria and those with hyperbilirubinaemia. However, 
hepcidin levels were higher in individuals with severe malaria and hyperbilirubinaemia than those with mild malaria 
(p = 0.0002 and p = 0.0004, respectively) and cut‑off values of hepcidin differentiated these groups from subjects 
with mild malaria. Hepcidin was positively associated with IL‑6 and IL‑10 levels and with parasitaemia in subjects with 
mild malaria and with IFN‑γ in subjects with severe malaria.
Conclusions: Malaria in the presence of hyperbilirubinaemia produces a less robust inflammatory response com‑
pared to severe cases of malaria. Hepcidin levels are positively associated with immune markers in vivax malaria 
outcomes.
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Background
Malaria is a major health problem worldwide, and in 2013 
it was estimated to cause 584,000 deaths [1]. Plasmodium 
vivax is the most widespread malaria parasite and is 
responsible for the majority of malaria cases in South-
east Asia and South America [1]. Clinical outcomes from 
Plasmodium infections can range from severe or mild 
diseases to asymptomatic parasite carriers. The balance 
and interactions between anti- and pro-inflammatory 
cytokines play an important role in vivax malaria mani-
festations [2]. Further, genetic alterations in genes related 
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to immune response have been associated with clinical 
outcomes [3, 4].
Hyperbilirubinaemia, which is also known as jaundice, 
is often associated with malaria infection. It occurs as a 
consequence of the intravascular haemolysis, dissemi-
nated intravascular coagulation and hepatocellular dys-
function [5]. However, recently, jaundice (serum total 
bilirubin >3  mg/dL) is no longer considered a single 
marker of malaria severity and the presence of hyperbili-
rubinaemia alone is not associated with a worse progno-
sis or a higher fatality rate in malaria [5–8]. Nevertheless, 
hyperbilirubinaemia is a common complication associ-
ated with severe malaria syndromes and concomitant 
jaundice can indicate more severe illness [9–12].
The rupture of red blood cells in the blood stream 
during malaria infection is associated with an increase 
in indirect bilirubin, but the primary schizogony of the 
malarial parasite also leads to the rupture of infected 
hepatocytes and elevates direct bilirubin levels. Both of 
these factors contribute to hyperbilirubinaemia and clini-
cal jaundice [12–16]. In this context, the hepatocellular 
damage observed in individuals with malaria and hyper-
bilirubinaemia may alter the hepatocytic expression of 
hepcidin, which regulates systemic iron homeostasis by 
degrading ferroportin, the only known human iron cell 
exporter [17]. The degradation of ferroportin leads to 
the inhibition of intestinal absorption of dietary iron and 
accumulation of iron in macrophages leading to low iron 
availability [17].
The immune response underlying malaria-related 
jaundice, which is defined by high productions of inter-
leukin (IL)-6, IL-10 and interferon (IFN)-γ, may influ-
ence hepcidin levels in hepatocytes and peripheral blood 
mononuclear cells [18, 19]. Portugal et al. described that 
increased hepcidin levels during a Plasmodium blood-
stage infection inhibited subsequent liver infection in a 
rodent model [20]. Further, hepcidin levels are regulated 
by inflammation, hypoxia, iron status, and IL-6 produc-
tion [21–27]. Hepcidin levels are increased in children 
during acute P. falciparum uncomplicated malaria [23] 
as well asymptomatic malaria caused by P. falciparum 
or P. vivax [24]; however, children with severe falcipa-
rum malaria demonstrated to have very low levels of this 
hormone [25–27]. Recently, hepcidin levels were demon-
strated to be the best predictor of iron absorption in chil-
dren under competing conditions, such as anaemia, iron 
deficiency and infection [28]. This suggests a potential 
utility for hepcidin in managing iron supplementation 
programmes at the time of malaria infection because of 
the inhibitory effect of hepcidin on the absorption of oral 
iron.
Noteworthy, no previous studies involving hepcidin 
in adults with symptomatic vivax malaria and in adults 
with severe malaria have been done so far. Hepcidin has 
been found to be low in children with severe malaria 
[25–27], but adults with severe malaria have not been 
evaluated. In the present study, it was studied the asso-
ciations between hepcidin and the levels of cytokines and 
chemokines in the serum of adults with severe and mild 
vivax malaria, as well as in subjects with vivax malaria 
with isolated hyperbilirubinaemia. The results herein 
indicate that individuals with hyperbilirubinaemia alone 
exhibit an inflammatory response similar to subjects with 
mild infections without hyperbilirubinaemia. Of equal 
importance is the finding that subjects with malaria and 
hyperbilirubinaemia and subjects with severe malaria 
have elevated levels of hepcidin; cut-off values of hepci-
din can differentiate these groups of subjects from those 
with mild malaria. Further, hepcidin levels are associated 




Individuals with an acute febrile syndrome (age range, 
4 months to 76 years; median age 36 years) who sought 
care at the reference hospital at the Fundação de 
Medicina Tropical Dr Heitor Vieira Dourado (FMT-
HVD), Amazonas, Brazil, were recruited between 2009 
and 2013. Subjects were tested for malaria by thick blood 
smear and those with P. vivax infections confirmed by 
PCR were invited to participate in this study. All patients 
with vivax malaria who developed haemolysis due to pri-
maquine treatment (i.e., patients using primaquine who 
experienced haemoglobin <10  g/dL and reticulocyte 
count >1.5  % or an indirect increase in bilirubin levels 
after using primaquine) were excluded. Patients with 
microscopic or molecular diagnosis of malaria caused by 
Plasmodium falciparum or P. vivax and P. falciparum co-
infection and patients with a serologic diagnosis of viral 
hepatitis (A, B, C, or D), HIV, or leptospirosis were also 
excluded. Participants were categorized into three groups 
based on the severity of infection: mild malaria (n = 72; 
without hyperbilirubinaemia), malaria with hyperbiliru-
binaemia (n =  14) and severe malaria (n =  17). Severe 
vivax malaria was defined according to the criteria for 
severe malaria established by the World Health Organi-
zation (WHO); malaria with hyperbilirubinaemia was 
defined by a serum total bilirubin level >51.3  μmol/L 
with no other criteria for severe malaria [6]. Details of 
subjects with severe malaria and hyperbilirubinaemia can 
be found in Mendonça et al. [3].
Ethics statement
This study was approved by the Ethics Committee of 
the FMT-HVD (protocol number: 2009/15243) and all 
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subjects provided written informed consent. All clinical 
investigations were conducted according to the principles 
outlined in the Declaration of Helsinki.
Plasma measurements
Blood was obtained by venipuncture; heparinized plasma 
was separated and immediately used or stored at −70 °C. 
The following clinical markers were measured in fresh 
plasma samples at the clinical laboratory facility at the 
FMT-HVD (Manaus, Brazil): haemoglobin (HB), haema-
tocrit (HT), platelets (PTL), aspartate aminotransferase 
(AST), and alanine aminotransferase (ALT). Levels of 
hepcidin in thawed plasma were measured by enzyme-
linked immunoassay (Assay Designs, Ann Arbor, MI, 
USA). Plasma levels of IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, 
IL-8, IL-10, IL-12p70, IL-13, IL-17, IFN-γ, tumor necrosis 
factor (TNF), chemokines CCL2 and CCL4, granulocyte-
colony stimulating factor (GCSF), and granulocyte–
macrophage colony-stimulating factor (GMCSF) were 
measured using a multiplex assay according to the manu-
facturer’s protocol (Bio-Rad, Hercules, CA, USA).
Genotyping
DNA was extracted from 200  μL of peripheral blood 
using a standard QIAGEN DNA blood mini kit (QIA-
GEN, Valencia, CA, USA) according to the manufactur-
er’s protocol. The polymorphism at position 744 G  >  T 
(rs11568350; G ancestral allele) in the ferroportin gene 
(SLC40A1) was typed by polymerase chain reaction-
restriction fragment length polymorphism (PCR–RFLP) 
analysis with the restriction enzyme PvuII (New England 
Biolabs, Ipswich, MA, USA) according to the protocol 
previously published by Kasvosve et  al. [29]. SLC40A1 
PCR products were size-separated by electrophoresis on 
3  % agarose gel under non-denaturing conditions. PCR 
products were subsequently stained with ethidium bro-
mide and visualized under a UV light.
Network analyses
Networks were generated from Spearman correlation 
matrices that contained values of each plasma marker 
measured in the samples; values were input into JMP 
10.0 software (SAS, Cary, NC, USA). Each marker was 
selected as a target and the software performed a search 
within the other mediators for those that were correlated 
with the target and calculated a correlation matrix using 
Spearman rank tests. The features related to the selected 
target were linked, and the links shown in the networks 
represented statistically significant Spearman rank corre-
lations (P < 0.05). To analyse the structure of the mark-
er’s network, the density of each network was calculated 
(range, 0–1). In the context of this study, the density was 
the ratio of the number of edges inferred in the network 
over the total number of possible edges between all pairs 
of nodes [2]. The network’s figures were customized 
using the Ingenuity Systems Pathway Analysis software 
(Ingenuity Systems, Redwood City, CA, USA) and Adobe 
Illustrator (Adobe Systems Inc.).
Statistical analyses
Chi square or Fisher exact tests were applied to evalu-
ate the associations between qualitative variables. The 
D’Agostino-Pearson omnibus normality test was used to 
test for Gaussian distribution of quantitative variables 
within the total sample. Variables that were not normally 
distributed were analysed with non-parametric tests. The 
Kruskal–Wallis test with Dunn’s multiple comparison 
(when three groups were compared) and the Mann–Whit-
ney test (when two groups were compared) were used to 
assess the differences among the clinical groups. Multino-
mial regression analyses adjusted for age and gender were 
performed to test associations between the plasma meas-
urements (below or above the median values of the entire 
study population) and the different clinical conditions 
(mild malaria, hyperbilirubinaemia and severe malaria). 
The receiver operating characteristic (ROC) curves and 
C-statistics of markers were used to test the ability to dis-
tinguish between the different clinical groups. A hierarchi-
cal cluster analysis using Ward’s method was performed to 
test whether a combination of different immune-related 
biomarkers could cluster the study groups separately. 
Hardy–Weinberg equilibrium (HWE) was assessed for 
the groups by comparing the observed number of differ-
ent SLC40A1 genotypes with those expected under HWE 
for the estimated allele frequency. Statistical analyses were 
performed using GraphPad Prism 6.0 (GraphPad Software 
Inc., USA), SPSS 19.0 (IBM, Armonk, NY, USA), and JMP 
11.0 (SAS, Cary, NC, USA). A p value <0.05 was consid-
ered statically significant.
Results
Baseline characteristics and SLC40A1 744 G > T distribution 
of the study participants
Most of the study subjects were male: 77.78 % (n = 56) of 
the mild malaria group, 71.43  % (n  =  10) of the malaria 
with hyperbilirubinaemia group and 52.94  % (n  =  9) of 
the severe malaria group (p = 0.0592; Table 1). There were 
no significant differences in age among the study groups 
(p  =  0.1274; Table  1). Parasitaemia levels were similar 
among the groups (p  =  0.2115; Table  1). Subjects with 
severe malaria displayed lower levels of HB and HT than 
subjects with hyperbilirubinaemia and subjects with mild 
malaria (p < 0.0001 for both comparisons; Table 1). Individ-
uals with hyperbilirubinaemia had the lowest PTL values 
(p = 0.0003) and the highest ALT values (p = 0.0039); AST 
levels did not differ among the groups (p = 0.0686; Table 1).
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A very low frequency of the ferroportin-associated 
polymorphism (SLC40A1 744 G  >  T) was identified 
in the study subjects (Table  1). No individuals with the 
homozygous mutant-type (TT) genotype were identi-
fied; one (1.39 %) heterozygous individual (GT genotype) 
was identified in the mild malaria group and one (5.88 %) 
was identified in the severe malaria group (p =  0.4108; 
Table 1). No differences were observed in allele distribu-
tions among the study groups (p = 0.4199; Table 1). The 
frequencies of SLC40A1 744 G  >  T genotypes met the 
conditions for HWE in all categories of vivax malaria 
infection.
The use of hepcidin levels to differentiate subjects 
with severe malaria and hyperbilirubinaemia from subjects 
with mild malaria
Plasma levels of hepcidin were higher in individuals with 
severe malaria and hyperbilirubinaemia than subjects 
with mild malaria (p =  0.0002 and p =  0.0004, respec-
tively; Fig.  1a). No difference in hepcidin levels was 
observed between the hyperbilirubinaemia and severe 
malaria groups (p  =  0.9093). The ROC curves analysis 
and the C-statistics allowed for the calculation of the 
discriminatory power of hepcidin to distinguish subjects 
with hyperbilirubinaemia from those with severe malaria 
or mild malaria (Fig.  1b). Hepcidin levels >3.148  ng/
mL offered a sensitivity of 85.71  %, a specificity of 
76.39  % and an area under the curve (AUC) of 79.07  % 
to differentiate mild from severe malaria (Fig. 1b). Hep-
cidin levels >2.406 ng/mL offered a sensitivity of 82.35 %, 
a specificity of 70.83  % and an AUC of 78.02  % to dif-
ferentiate mild malaria from malaria with hyperbiliru-
binaemia (Fig.  1b). Hepcidin median and cut-off values 
were established (Fig.  1b); an age- and gender-adjusted 
multinomial logistic regression analysis was conducted 
on the basis of these values to confirm the associations 
between high hepcidin levels and susceptibility to hyper-
bilirubinaemia and severe malaria (Fig. 1c). Hepcidin lev-
els above the cut-off (3.148 ng/mL; OR 26.405, 95 % CI 
4.789–145.596  ng/mL, p =  0.001) or median (1.810  ng/
mL; OR 14.771, 95 % CI 2.563–85.120 ng/mL, p = 0.003) 
values were associated with hyperbilirubinaemia more 
frequently than mild malaria (Fig. 1c). Likewise, hepcidin 
levels above the cut-off (2.406  ng/mL; OR 12.861, 95  % 
CI 3.082–53.668 ng/mL, p = 0.001) or median (1.842 ng/
mL; OR 14.332, 95 % CI 2.754–74.582 ng/mL, p = 0.002) 
values were associated with severe malaria more fre-
quently than with mild malaria (Fig.  1c). Hepcidin con-
centrations of subjects in the smaller groups within the 
severe malaria group were not analysed due to the low 
number of individuals and the low power.
The expression of immune‑related biomarkers in each 
of the study groups
A panel of 17 cytokines and chemokines (IL-1β, IL-2, 
IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-17, 
Table 1 Baseline characteristics, laboratory measurements, and distribution of SLC40A1 744 (G > T) polymorphism in the 
study participants
ALT alanine aminotransferase, AST aspartate aminotransferase, IQR interquartile range
** Categorized variables were compared using the Chi square test
*** Ordinal variables were compared using the Mann–Whitney test for two groups or the Kruskal–Wallis test with Dunn’s multiple comparison for three or more 
groups
Mild malaria Malaria with hyperbilirubinaemia Severe malaria P‑value
(n = 72) (n = 14) (n = 17)
Male, n (%) 56 (77.78) 10 (71.43) 9 (52.94) 0.0592**
Age (year), median (IQR) 36.00 (27.00–45.50) 26.00 (20.25–36.25) 37.00 (10.50–44.50) 0.1274***
Parasitaemia (parasites/μL), median (IQR) 2673 (842–9313) 2,451 (247–11,655) 291 (0–29,184) 0.2115***
Laboratory measurements, median (IQR)
 Haemoglobin (g/dL) 13.20 (12.50–14.28) 11.75 (10.38–13.88) 7.10 (6.50–10.50) <0.0001***
 Haematocrit (%) 43.50 (40.65–46.18) 34.10 (30.20–41.45) 23.10 (19.75–31.90) <0.0001***
 Platelets (per mm3) 108,500 (71,250–132,250) 33,000 (18,000–51,250) 64,000 (33,500–202,000) 0.0003***
 AST (IU/L) 67.50 (50.00–93.25) 65.00 (36.00–172.50) 34.00 (21.50–112.30) 0.0686***
 ALT (IU/L) 34.00 (19.25–50.75) 104.50 (36.00–262.50) 41.50 (13.25–76.00) 0.0039***
SLC40A1 744 (G > T) n (%)
 GG 71 (98.61) 14 (100.00) 16 (94.12) 0.4108**
 GT 1 (1.39) 0 (0.00) 1 (5.88)
 TT 0 (0.00) 0 (0.00) 0 (0.00)
 G allele 141 (99.30) 28 (100.00) 33 (97.06) 0.4199**
 T allele 1 (0.70) 0 (0.00) 1 (2.94)
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IFN-γ, TNF, CCL2, CCL4, GCSF, GMCSF) and inflamma-
tory ratios (TNF/IL-10, IFN-γ/IL-10 and (TNF + IFN-γ)/
IL-10) were used to build a heat map to identify unique 
signatures that could highlight differences between the 
study groups in a hierarchical cluster analysis (Fig.  2a). 
Among the clinical groups evaluated, individuals with 
severe malaria exhibited the highest median concentra-
tions of the majority of the immune markers (GCSF, IFN-
γ, IL-7, IL-2, IL-12p70, IL-13, IL-17, TNF, IL-4, IL-8, IL-6, 
IFN-γ/IL-10, TNF/IL-10, CCL2, and (TNF  +  IFN-γ)/
IL-10; Fig.  2a). Subjects with mild malaria exhibited the 
highest plasma levels of IL-10 (Fig. 2a).
Multinominal regression analyses adjusted for age and 
gender revealed that severe malaria was associated with 
higher levels of IL-2 (p =  0.025) and IL-13 (p =  0.018) 
than malaria with hyperbilirubinaemia (Fig.  2b). Severe 
malaria was also associated with higher levels of IL-1β 
(p  =  0.008), IL-2 (p  =  0.001), IL-4 (p  =  0.041), IL-
12p70 (p = 0.010), IL-13 (p = 0.004), IFN-γ (p = 0.041), 
TNF (p  =  0.049), IFN-γ/IL-10 (p  =  0.016), TNF/IL-10 
(p = 0.016) and (TNF +  IFN-γ)/IL-10 (p = 0.001) than 
mild malaria (Fig.  2b). No differences in markers of 
immune expression were observed between the mild 
malaria and the hyperbilirubinaemia groups according to 
multinomial regression analyses (Fig. 2b).
A network analysis of immune response
Cytokine and chemokine levels were used to build net-
works representing possible interactions between the 
candidate biomarkers in each study group. The distri-
butions of plasma concentrations of the cytokines and 
chemokines in each of the different clinical groups are 
provided (see Additional file  1). The network analysis 
revealed five negative correlations between candidate 
biomarkers in the study groups; four of these interactions 
were between IL-10 and its inflammatory ratios (IL-10 as 
a dividend). A majority of the statistically significant cor-
relations observed were positive (Fig.  3a). However, the 
densities of the networks from each clinical group were 
different. The mild malaria group exhibited the highest 
density of interactions (network density: 0.605), which 
may be due to the higher number of individuals in this 
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Fig. 1 Hepcidin levels discriminate severe malaria and hyperbilirubinaemia from mild malaria. Hepcidin levels were compared in the study groups 
by the Mann–Whitney test (a). Hepcidin levels were analysed by receiver operating characteristic (ROC) curves to establish the area under the curve 
(AUC) and the cut‑off sensitivity and specificity values to distinguish between individuals with severe malaria or hyperbilirubinaemia and individuals 
with mild malaria (b). Based on hepcidin cut‑off (obtained in b) and median values, a multinomial regression analysis adjusted for age and gender 
was conducted to calculate odds ratios (ORs) and 95 % confidence intervals (CI), represented by the icons and bars, respectively (c). A p‑value <0.05 
was considered statistically significant. Mild mal mild malaria group, hyperbil hyperbilirubinaemia group, sev mal severe malaria group
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group compared to the other groups. The hyperbilirubi-
naemia group exhibited a network density of 0.284 and 
the severe malaria group exhibited the lowest density of 
0.253. P-values and Spearman rank values for each corre-
lation of immune biomarkers according to study groups 
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Fig. 2 Concentration of cytokines and chemokines according to study groups. A heat map was designed to depict the overall pattern of expres‑
sion of immune markers in the different study groups according to the median value of each parameter (a). A two‑way hierarchical cluster analysis 
(Ward’s method) of immune molecules by clinical group was performed (a). Biomarkers that had the same median in the three groups were 
excluded from the heat map and cluster analysis. The colours shown for each symbol represent the fold variation from the median values calculated 
for each marker (a). Differentiation between mild malaria and hyperbilirubinaemia, hyperbilirubinaemia and severe malaria, and mild malaria and 
severe malaria were noted by cytokine and chemokine levels using a multinominal regression analysis adjusted for age and gender that calculated 
odds ratios (ORs) and 95 % confidence intervals (CI), represented by the icons and bars, respectively (b). Red icons represent a statistically significant 
difference. A p‑value <0.05 was considered statistically significant
Page 7 of 11Mendonça et al. Malar J  (2015) 14:407 
Of the 20 immune-related biomarkers and inflam-
matory ratios assessed in the network analyses, five 
cytokines (IFN-γ, TNF, IL-1β, IL-6, and IL-12p70) 
exhibited the most interactions (statistically significant 
Spearman correlations) across all groups. IFN-γ par-
ticipated in 13.82 % of all interactions, TNF in 13.36 % 
of all interactions, IL-1β in 15.21 % of all interactions, 
IL-6 in 13.82  % of all interactions, and IL-12p70 in 
12.44 % of all interactions (Fig. 3b). In order to assess 
if the number of network connections involving each 
of these cytokines could highlight differences among 
the clinical groups, the percentage of edges involving 
each molecule as a portion of the overall number of 
edges in the network was calculated. IFN-γ and TNF 
showed the highest relative number of network inter-
actions in the severe malaria group and IL-1β and IL-6 
showed the highest relative number of interactions 
in the hyperbilirubinaemia group (Fig.  3b). IL-12p70 
showed the highest number of interactions in the mild 
malaria group (Fig.  3c). These results suggest that 
unique immune signatures involving plasma cytokine 
and chemokine levels highlight differences that differ-
entiate mild malaria, malaria with hyperbilirubinae-















































































Fig. 3 Networks of immune‑related biomarkers in mild malaria, hyperbilirubinaemia and severe malaria groups. Plasma levels of several immune‑
related (cytokines and chemokines) biomarkers were measured in subjects with mild malaria, hyperbilirubinaemia, and severe malaria. Each 
connecting line represents a significant interaction (p < 0.05) detected by Spearman’s correlation test (a). Grey lines represent positive significant 
interactions and green lines represent negative significant correlations. Icons are colored according to their expression in the heat map shown in 
Fig. 2a. The five immune‑related biomarkers with the highest number of interactions in all three groups were chosen (IFN‑γ, TNF, IL‑1β, IL‑6, and 
IL‑12p70) and the relative number of interactions of these biomarkers was calculated for each group (b). Dark grey rectangles represent the highest 
relative number of connections, light dark rectangles represent the medium relative number of connections, and white rectangles represent the low‑
est relative number of connections between molecules (b)
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Next, the interactions between clinical laboratory 
markers, parasitaemia, hepcidin levels, and immune-
related molecules were evaluated (Fig.  4). As expected, 
in all study groups, HB levels were positively correlated 
with HT and ALT was positively correlated with AST 
(Fig.  4). Hepcidin was positively correlated with IL-6 
(r = 0.4339; p = 0.0015), IL-10 (r = 0.5154; p = 0.0002), 
and parasitaemia (r = 0.3032; p = 0.0096) and negatively 
correlated with IFN-γ/IL-10 (r = −0.4369; p =  0.0017) 
and (TNF +  IFN-γ)/IL-10 (r = −0.3776; p = 0.0075) in 
the mild malaria group. Hepcidin was positively corre-
lated with parasitaemia (r =  0.5912; p =  0.0260) in the 
hyperbilirubinaemia group and with IFN-γ (r =  0.5324; 
p  =  0.0278) in the severe malaria group. P-values and 
Spearman rank values for each correlation between 
immune biomarkers, laboratory measures, parasitaemia, 
and hepcidin levels are provided (see Additional file 3).
Discussion
Relationships between plasma markers of immune 
response and hepcidin levels during severe vivax malaria 
and malaria with hyperbilirubinaemia are largely unex-
plored. The results of the present study indicate that 
plasma hepcidin levels are higher in individuals with 
severe vivax malaria and individuals with hyperbilirubi-
naemia than in those with mild malaria; cut-off values of 
hepcidin can discriminate malaria outcomes. However, 
individuals with malaria with hyperbilirubinaemia had 
plasma cytokine and chemokine levels similar to those of 
individuals with mild malaria. Subjects with hyperbiliru-
binaemia exhibited a less robust inflammatory response 
than subjects with severe malaria, which reinforces the 
exclusion and adaptation of this condition in the most 
recent WHO malaria severity criteria [6]. Hepcidin was 
















































































Fig. 4 Associations between laboratory parameters, parasitaemia, hepcidin levels, and immune‑related biomarkers. Statistically significant correla‑
tions between laboratory markers, parasitaemia, hepcidin levels, and immune‑related biomarkers are shown for each study group. The correla‑
tions were assessed using the Spearman rank test. Green lines represent negative significant (p < 0.05) correlations and grey lines represent positive 
significant correlations. Icons for cytokines and chemokines are coloured according to their expression in the heat map shown in Fig. 2a. The other 
icons are coloured according to their expressions in the comparisons between study groups: grey icons are parameters with no difference between 
the two groups; blue and red icons represent downregulated and upregulated markers, respectively
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in the mild malaria group and with IFN-γ in the severe 
malaria group, which suggests a possible role of immuno-
logical regulation in the expression of this hormone.
Jaundice is a clinical outcome often associated with 
malaria infection, but the exact pathogenesis of this condi-
tion is not clearly understood [5]. The rupture of red blood 
cells, ischemia due to adherence of parasitized eryth-
rocytes to the endothelial walls, and, to a lesser extent, 
hepatocellular dysfunction can contribute to hyperbiliru-
binaemia [9]. The present study confirms that individuals 
with hyperbilirubinaemia in the context of vivax malaria 
have low levels of PTL and high levels of ALT, which sug-
gests that a degree of liver dysfunction associated with this 
condition might influence hepcidin expression by hepato-
cytes [12–16]. Hyperbilirubinaemia is not itself a compli-
cation of severe malaria, but it is associated with higher 
morbidity and mortality when it occurs concomitantly 
with at least one other complication [5, 8, 11]. In this study, 
individuals infected by P. vivax with hyperbilirubinaemia 
had lower levels of IL-2 and IL-13 than individuals with 
severe cases of malaria; no differences in immune response 
were observed between subjects with hyperbilirubinaemia 
and those with mild malaria. Even though the hyperbiliru-
binaemia group demonstrated an overall low immunoin-
flammatory status, the immune response may still have an 
important role in the pathogenesis of hyperbilirubinaemia. 
In the network analysis, IL-1β and IL-6 were highly asso-
ciated with other inflammatory parameters. In fact, these 
markers may regulate the quality of the immune response 
and the high hepcidin levels associated with hyperbilirubi-
naemia. Levels of IL-6 have already been associated with 
severe malaria outcomes, and jaundice has been demon-
strated to be independently linked to increased levels of 
this cytokine [18, 30]. Furthermore, IL -6 appears to be 
correlated with hepcidin levels during malaria infection 
[22, 25–27].
Traditionally, malaria by P. vivax has been considered a 
benign infection, but, in recent years, P. vivax malaria has 
been increasingly associated with severe disease [31–33]. 
The immune response, with its balance of anti- and pro-
inflammatory mediators, seems to play an essential role 
in severe vivax malaria [2]. As expected, in the present 
study, individuals with severe vivax malaria exhibited 
higher concentrations of immune markers. This group 
also demonstrated a significant interaction between 
IFN-γ and TNF. Elevated levels of TNF and IFN-γ are 
related to severe forms of infection, such as cerebral 
malaria and severe anaemia in P. falciparum malaria 
[18, 33, 34]. In contrast, subjects with mild malaria dis-
played herein higher levels of IL-10 than subjects with 
severe malaria. These findings confirm previous studies 
that indicated a role of this regulatory cytokine in mild 
malaria outcomes [33, 35].
Hepcidin is the major regulator of iron levels, which it 
accomplishes by degrading the ferroportin receptor and 
inhibiting iron release from intracellular compartments. 
Mutations in the ferroportin gene (SLC40A1) have been 
linked to high iron stores and haemochromatosis in 
humans influencing hepcidin levels [29, 36, 37]. In this 
study population, the SLC40A1 SNP (744 G  >  T) was 
rarely detected and it did not influence vivax malaria out-
comes. Several studies have shown that hepcidin levels 
are increased in asymptomatic and symptomatic malaria 
caused by P. falciparum or P. vivax [21–24, 38]. In this 
study, higher plasma levels of hepcidin were observed 
in subjects with severe malaria and malaria with hyper-
bilirubinaemia than in subjects with mild malaria. The 
increased hepcidin levels in the malaria with hyperbiliru-
binaemia group may be a consequence of liver damage, 
hepatocellular dysfunction, and the immune response 
associated with hyperbilirubinaemia. Despite the pos-
sibility of liver dysfunction influencing hepcidin levels 
[18, 19] in malaria with hyperbilirubinaemia group, it 
was not observed a direct correlation between hepcidin 
and ALT or AST levels, and other liver biomarkers can-
not be explored due to limitation of the volume of stored 
plasma.
Recently, hepcidin was discovered to be the best pre-
dictor of erythrocyte iron incorporation, which suggests 
a role for this hormone in the management of iron sup-
plementation programmes [28]. Hepcidin cut-off val-
ues may also be used to distinguish severe malaria from 
mild malaria (without hyperbilirubinaemia) outcomes 
in endemic settings, as demonstrated in this study. Fur-
ther, hepcidin cut-off values can be an additional tool 
(biomarker) in addition to the WHO criteria to distin-
guish severe or hyperbilirubinaemia patients from mild 
infection. Interestingly, some studies have reported that 
individuals with severe falciparum malaria, defined by 
severe anaemia and cerebral malaria, have low hepcidin 
levels [25–27]. Such differences in hepcidin concentra-
tions may be explained by several factors. First, these 
studies measured hepcidin in children, whose degree 
of anaemia, which is defined by HB levels, is lower than 
adults in a majority of severe cases; second, cytokine 
levels in low-hepcidin severe malaria cases are lower 
than in uncomplicated cases, which suggests a lack of 
inflammation-driven stimulus for hepcidin production. 
In the present study, subjects with severe malaria had a 
robust pro-inflammatory response that may stimulate the 
expression of hepcidin.
Hepcidin is upregulated in response to several infec-
tious and inflammatory conditions [39]. In a murine 
model, the production of hepcidin during a blood-stage 
infection can prevent a subsequent liver-stage infec-
tion; this inhibition was preserved in mice treated with 
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anti-IL-6 antibodies [20]. Recently, it was shown that 
IL-10 and IL-6 are increased in primary macrophages co-
cultured with P. falciparum-infected erythrocytes; IL-10 
seemed to induce hepcidin in macrophages, which was 
mediated by signal transducer and activator of transcrip-
tion 3-phosphorylation [40]. Also, malaria-infected red 
blood cells induced hepcidin mRNA synthesis by periph-
eral blood mononuclear cells, which indicates the impor-
tance of circulatory immune cells on hepcidin production 
[19]. Hepcidin was positively correlated with IL-6 and 
IL-10 in the mild malaria group in the present study. IL-10 
is a regulatory cytokine and the correlation between hep-
cidin and this cytokine can modulate the clinical disease 
observed in mild malaria cases. Hepcidin was also asso-
ciated with parasitaemia in subjects with mild malaria 
and hyperbilirubinaemia, which agrees with the results 
of other studies [21, 23]. The association between para-
site burden and inflammatory response may explain the 
relationship between hepcidin and parasitaemia, although 
a direct effect of the malaria parasite on hepatic and/or 
macrophage hepcidin production cannot be ruled out 
[23]. Hepcidin was positively correlated with IFN-γ in 
subjects with severe malaria in the present study, which 
further suggests a role of immune response in hepcidin 
regulation. IFN-γ is a proinflammatory cytokine involved 
in malaria pathogenesis and symptomatology [33], and 
the correlation between hepcidin and this cytokine may 
influence malaria severity. Interactions between immu-
nological factors and hepcidin may be different according 
to malaria outcomes; however, the small sample sizes in 
the severe malaria and malaria with hyperbilirubinaemia 
groups may have underestimated these associations.
This study was limited because of a small number of 
subjects in the severe and hyperbilirubinaemia groups, 
which may have underestimated the associations between 
the markers studied herein. Further, unfortunately, others 
iron parameters (i.e. ferritin, transferrin receptor) were 
not analysed to better understand the relation of hepci-
din, immune response and iron metabolism.
Conclusion
Hyperbilirubinaemia is a common clinical feature often 
associated with complications during malaria infection. 
The cytokine and chemokine responses in hyperbiliru-
binaemia are similar to the responses in uncomplicated 
malaria cases but less robust than the inflammatory 
responses observed in severe vivax malaria. Hepcidin 
levels are increased in cases of both severe malaria and 
malaria with hyperbilirrubinemia, and hepcidin levels 
are positively correlated with IL-6 and IL-10 in the mild 
malaria cases, and with IFN-γ in severe malaria subjects. 
These findings highlight the importance of immune 
response on hepcidin regulation. Hepcidin levels can be 
used to define iron supplementation programmes, but 
the findings from the present study suggest that hepcidin 
can also be used as a supplementary diagnostic marker of 
malaria infection.
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